Teva Pharmaceutical Industries Ltd. (TEVA) shares soar 4.19% on FDA approval for AJOVY®

Teva Pharmaceutical Industries Ltd. (TEVA) shares surged 4.19% today, marking a significant rebound after hitting its lowest level since April 2024, with an intraday decline of 6.55%.

Teva Pharmaceutical Industries received FDA acceptance of its supplemental Biologics License Application to expand AJOVY®'s use for prevention. This development is expected to positively impact the stock price due to potential increased revenue and market share. The expanded use of AJOVY® could open new avenues for the company, attracting more patients and healthcare providers, thereby boosting sales and profitability.

Despite the positive news, there is bearish sentiment detected with heavy put volume and directionally bearish options trading for Teva (TEVA). This indicates a potential negative investor outlook and possible decline in stock price. Investors may be cautious due to various factors, including market volatility and concerns about the company's long-term growth prospects. The bearish sentiment suggests that some investors are hedging their positions or betting against the stock, which could lead to further price fluctuations.